Patients younger than 18 scheduled for congenital heart surgery will be assessed during and post-operatively as well as at the first follow-up after 9-12 month for the novel biomarker sST2. We will assess the marker independently and in evaluation with other blood biomarkers to evaluate sings of heart failure. Compared to established biomarkers, sST2 promises thereby to be less variable to factors like age or acute kidney injury, rendering it potentially more reliable in the field of congenital cardiac surgery.
Consented for cardiopulmonary bypass surgery for cardiac reason
Conversational skills in German (by child and/or representative) to be able to fully understand and sign a written consent in German language
Know genetic life limiting conditions
Syndrome patients who are scheduled or highly likely to be operated on more than one organ
Body weight at time of surgery less than 2.5 kg
Being recruited and enrolled for an interventional study protocol
Martin Schweiger
Lead sponsor
University Children's Hospital, Zurich
Sponsor institution
University Children's Hospital, Zurich
Collaborator